MedWatch

Global venture boss keeps an eye on Danish biotech companies

Omega Funds receives 2200 applications from life science companies per year and 99.9 percent of these are turned down. But some Danish biotech companies have caught the attention of founder Otello Stampacchia and might be among the 0.1 lucky ones.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

2017 var et rekordår for kapitalrejsninger i Skandinavien

Skandinaviske life science-selskaber rejste ligeså mange penge i 2017 som i de tre foregående år tilsammen, viser en ny rapport fra svenske Industrifonden. Sverige førte ikke overraskende an, men der var også fremgang at spore i Danmark og Norge.

Related articles